Procalcitonin: Inflammatory biomarker for assessing the severity of community-acquired pneumonia - A clinical observation in geriatric patients

Gerontology

Volumn 56, Issue 4, 2010, Pages 385-389

  Heppner, H J ^a,c   Bertsch, T ^b   Alber, B ^b   Esslinger, A S ^c   Dragonas, C ^a   Bauer, J M ^a   Sieber, C C ^a  

^a KLINIKUM NÜRNBERG   (Germany)

^b Laboratoriumsmedizin   (Austria)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Community acquired pneumonia; CURB 65; Pneumonia; Procalcitonin

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; PROCALCITONIN; AUTACOID; CALCITONIN; PROTEIN PRECURSOR;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL OBSERVATION; COMMUNITY ACQUIRED PNEUMONIA; DEMOGRAPHY; DISEASE SEVERITY; FEMALE; GERIATRIC PATIENT; HOSPITAL ADMISSION; HUMAN; LEUKOCYTE COUNT; MALE; MORTALITY; PRIORITY JOURNAL; BLOOD; COMMUNITY-ACQUIRED INFECTIONS; METABOLISM; PNEUMONIA; PNEUMONIA, BACTERIAL; RISK FACTOR; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CALCITONIN; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; INFLAMMATION MEDIATORS; LEUKOCYTE COUNT; MALE; PNEUMONIA; PNEUMONIA, BACTERIAL; PROTEIN PRECURSORS; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 77953810976     PISSN: 0304324X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000262285     Document Type: Article

References (16)

1. Christ-Crain M: Effect of procalcitoninguided treatment on antibiotic use and outcome in lower respiratory tract infections. Lancet 2004; 363: 600-607.
2. Ewig S, de Roux A, Bauer T, Garcia E, Mensa J, Niedermann M, Torres A: Validation of predictive rules and indices of severity for community acquired pneumonia. Thorax 2004; 59: 421-427.
3. Fabel H, Schulz A: Parameter zur Diagnose und Verlaufsbeurteilung von Infektionen in der Intensivmedizin. Intensivmed 1997; 34: 466-471.
4. Halm EA, Fine MJ, Kapoor WN, Singer DE, Marrie TJ, Siu AL: Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia. Arch Intern Med 2002; 162: 1278-1284.
5. Hausfater P, Juillen G, Madonna-Py B, Haroche J, Bernard M, Riou B: Serum procalcitonin measurement as a diagnostic and prognostic marker in febrile adult patients presenting to the emergency department. Crit Care 2007; 11:R60.
6. Herzum I, Renz H: Inflammatory markers in SIRS, sepsis and septic shock. Curr Med Chem 2008; 15: 581-587.
7. Höffken G, Lorenz J, Kern W, Welte T, Bauer T, Dalhoff K, Dietrich E, Ewig S, Gastmeier P, Grabeln B, Halle E, Kolditz M, Marre R, Sitter H: Epidemiologie, Diagnostik, antimikrobielle Therapie und Management von erwachsenen Patienten mit ambulant erworbenen tiefen Atemwegsinfektionen (akute Bronchitis, akute Exazerbation einer chronischen Bronchitis, Influenza und andere respiratorische Virusinfektionen) sowie ambulant erworbener pneumonia. S3-Leitlinie. AWMF online; www.uniduesseldorf.de/ AWMF/ll/082-001.htm, 2005.
8. Kohlhammer Y, Schwartz M, Raspe H, Schäfer T: Risikofaktoren für die community acquired pneumonia (Community Acquired Pneumonia) - Eine systematische Übersichtsarbeit. Dtsch Med Wochenzeitschr 2005; 130: 381-386.
9. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
10. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, Lewis SA, Macfarlane JT: Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58: 377-382.
11. Meisner M: Pneumonia und Hyperprocalcitoninämie; in: Procalcitonin (PCT), ed 3. Stuttgart, Thieme, 2000, pp 126-130.
12. Menéndez R, Torres A, Zalacaín R, Aspa J, Martín Villasclaras JJ, Borderías L, Benítez Moya JM, Ruiz-Manzano J, Rodríguez de Castro F, Blanquer J, Pérez D, Puzo C, Sánchez Gascón, Gallardo J, Álvarez C, Molinos L: Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax 2004; 59: 960-965.
13. Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J: Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med 2008; 177: 498-505.
14. Valencia M, Torres A: Pneumonia severity index class v patients with community-acquired pneumonia: characteristics, outcomes, and value of severity scores. Chest Aug 2007; 132: 515-522.
15. Welte T, Marre R, Suttorp N: Kompetenznetzwerk 'Ambulant Erworbene Pneumonie': Was gibt es Neues in der Behandlung der ambulant erworbenen Pneumonie? Med Klinik 2006; 101: 313-320.
16. www.bqs-qualitaetsreport.de/2006/ergebnisse/ leistungsbereiche/pneumonie/ basis (Zugriff 14.1.2008).